Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint

[everhopeful]

Firemonkey already posted this. Apologies.

Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia

MARLBOROUGH, Mass. & PARAMUS, N.J.–(Business Wire)–Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced that positive results from SEP 361-201, a pivotal Phase 2 study that evaluated the efficacy and safety of SEP-363856, a novel psychotropic agent for the treatment of patients with schizophrenia, were presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla. The study met its primary endpoint, demonstrating that hospitalized patients with acute exacerbation (worsening) of schizophrenia treated with SEP-363856 showed statistically significant and clinically meaningful improvement in the Positiv…